Related Experiment Video
Updated: Jun 6, 2025
Ultrasonic-augmented Primary Adult Fibroblast Isolation
Published on: July 29, 2019
Gucy1α1 specifically marks kidney, heart, lung and liver fibroblasts
Valeria Rudman-Melnick1, Davy Vanhoutte2, Kaitlynn Stowers1
1Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, 268-280 Albert Sabin Way, location T, floor 6, suite 272, Cincinnati, OH, 45229, USA.
Abstract:
Fibrosis is a common outcome of numerous pathologies, including chronic kidney disease (CKD), a progressive renal function deterioration. Current approaches to target activated fibroblasts, key effector contributors to fibrotic tissue remodeling, lack specificity. Here, we report Gucy1α1 as a specific kidney fibroblast marker. Gucy1α1 levels significantly increased over the course of two clinically relevant murine CKD models and directly correlated with established fibrosis markers. Immunofluorescent (IF) imaging showed that Gucy1α1 comprehensively labelled cortical and medullary quiescent and activated fibroblasts in the control kidney and throughout injury progression, respectively. Unlike traditionally used markers platelet derived growth factor receptor beta (Pdgfrβ) and vimentin (Vim), Gucy1α1 did not overlap with off-target populations such as podocytes. Notably, Gucy1α1 labelled kidney fibroblasts in both male and female mice. Furthermore, we observed elevated GUCY1α1 expression in the human fibrotic kidney and lung. Studies in the murine models of cardiac and liver fibrosis revealed Gucy1α1 elevation in activated Pdgfrβ-, Vim- and alpha smooth muscle actin (αSma)-expressing fibroblasts paralleling injury progression and resolution. Overall, we demonstrate Gucy1α1 as an exclusive fibroblast marker in both sexes. Due to its multiorgan translational potential, GUCY1α1 might provide a novel promising strategy to specifically target and mechanistically examine fibroblasts.
Insights
Researchers identified Gucy1α1 as a specific marker for kidney fibroblasts, crucial in fibrotic diseases like chronic kidney disease (CKD). This discovery offers a precise way to study and potentially target these cells across multiple organs.
Area of Science:
- Nephrology
- Cell Biology
- Biomarker Discovery
Background:
- Fibrosis, a hallmark of chronic kidney disease (CKD), involves activated fibroblasts contributing to tissue remodeling.
- Current methods for targeting fibroblasts lack specificity, hindering effective therapeutic strategies.
Purpose of the Study:
- To identify and validate a specific marker for kidney fibroblasts.
- To assess the potential of this marker for diagnosing and targeting fibrotic diseases.
Main Methods:
- Utilized two clinically relevant murine CKD models.
- Employed immunofluorescent (IF) imaging to visualize marker expression.
- Compared Gucy1α1 with established fibroblast markers (Pdgfrβ, Vim) and cell populations (podocytes).
- Analyzed Gucy1α1 expression in human fibrotic tissues and murine models of cardiac and liver fibrosis.
Main Results:
- Gucy1α1 levels significantly increased in CKD models, correlating with fibrosis markers.
- IF imaging confirmed Gucy1α1 exclusively labels kidney fibroblasts (quiescent and activated) in both sexes.
- Gucy1α1 showed no overlap with podocytes, unlike Pdgfrβ and Vim.
- Elevated GUCY1α1 expression was observed in human fibrotic kidneys and lungs, and in murine cardiac and liver fibrosis models.
Conclusions:
- Gucy1α1 is identified as a specific and exclusive marker for kidney fibroblasts across both sexes.
- Gucy1α1 demonstrates translational potential for diagnosing and targeting fibroblasts in multiorgan fibrotic conditions.
- This marker may offer a novel strategy for mechanistic investigation and therapeutic intervention in fibrotic diseases.
